CDK5
Cyclin-dependent kinase 5
As of the edition of 20 October 2026, CDK5 (cyclin-dependent kinase 5, UniProt Q00535) has 2 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q00535
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 12
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Heart and blood vessels; Hormones; Digestive system; Lungs and airways
- Registered trials of its drugs
- 24
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dinaciclib | Stopped | Phase 3 | none listed |
| Seliciclib | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Merck & Co. | Route A |
| AbbVie | Route A |
| Alcon | Route A |
The other 1 company at CDK5
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at CDK5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.